Back to top

Analyst Blog

Zacks Equity Research

Positive Data on MediciNova's MN-221


 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

MediciNova, Inc. recently announced positive preliminary results on intravenous MN-221 (bedoradrine). The randomized, placebo-controlled phase Ib trial evaluated the efficacy and safety of MN-221 in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).

As per preliminary data from the phase Ib trial, MN-221 demonstrated moderately improved pulmonary function compared to placebo. The data indicated an encouraging pharmacokinetic and efficacy profile. There were no significant safety concerns associated with the use of the candidate.

Currently approved COPD treatments include Forest Laboratories, Inc.’s (FRX - Analyst Report) Daliresp and GlaxoSmithKline’s (GSK - Analyst Report) Advair.

MediciNova is developing MN-221, a highly selective beta(2)-adrenergic receptor agonist, for the treatment of acute exacerbations of asthma and COPD. In 2004, MediciNova licensed exclusive rights to MN-221 from Kissei Pharmaceutical Co., Ltd. in all territories except Japan.

Earlier, in May 2012, the company had presented preliminary data from a hospital emergency department (ED)-based phase IIb trial of MN-221 for the treatment of acute exacerbations of asthma. Although the randomized, double-blind, placebo-controlled phase IIb trial did not meet the primary endpoint, it was observed that the use of MN-221 resulted in a significant improvement in clinical symptoms.  

The company has scheduled an end-of-phase II meeting with the US Food and Drug Administration (FDA) in late October 2012 regarding the development of MN-221 for the treatment of acute exacerbations of asthma. The company also plans to discuss the COPD data from the phase Ib trial in this meeting.  


MediciNova has a diversified pipeline, which includes 6 clinical-stage compounds targeting several indications including respiratory disorders, neurologic conditions and oncology conditions. However, we see no near-term catalyst for the stock. Thus, we maintain a Neutral recommendation on MediciNova. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%